Dinoprostone Induction vs. Expectant Management After PROM at Term

Sponsor
University Medical Centre Ljubljana (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05430711
Collaborator
(none)
70
2
13

Study Details

Study Description

Brief Summary

Prelabour rupture of membranes (PROM) is associated with intrauterine infection and maternal and neonatal consequences. This risk increases with the length of time from PROM to delivery. Induction of labor has been shown to reduce the rates of those complications, however the optimal time interval has not yet been determined.

The main purpose of this single-center randomized prospective study is to assess the differences between two approaches of managing PROM at term-expectant management and induction with a dinoprostone vaginal delivery system.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Women with singleton pregnancy in cephalic presentation at term (37-41 6/7 weeks gestational age) will be randomised 4 to 12 hours after PROM when a sterile vaginal exam will be completed to assign Bishop score. When Bishop score at presentation will be ≤5, the study will be presented to the patient. Once the patient will be consented and randomized, women will receive dinoprostone vaginal delivery system (for up to 24 hours after randomisation) or will be managed expectantly (for up to 24 hours after randomisation).

Patients randomized to the expectant management group will be admitted to the maternity ward, where they will wait up to a maximum of 24 hours for labor to start spontaneously.

Patients in the induction group will also be admitted to the maternity ward and induced with a dinoprostone vaginal delivery system. If not removed sooner, the vaginal delivery system will be removed after 24h.

If patients in both groups will not be in active labor 24 hours after randomisation they will be admitted to the delivery room and health care providers will manage active labor per usual practice. The need for cesarean section or operative delivery or will be at the discretion of the healthcare provider.

In the days following birth, woman in both groups, will be asked to fill in a questionnaire about their satisfaction with the labour experience.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Induction of Labour With Dinoprostone vs. Expectant Management After Prelabour Rupture of Membranes at Term
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dinoprostone

Participants will receive dinoprostone 10 mg vaginal delivery system for up to 24 hours.

Drug: Dinoprostone
After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
Other Names:
  • Propess
  • No Intervention: Expectant management

    Participants will not receive drugs to induce labour, they will be managed expectantly for up to 24 hours.

    Outcome Measures

    Primary Outcome Measures

    1. Time from randomisation to delivery [Within 1 week]

      Time measured from randomisation to the delivery time

    Secondary Outcome Measures

    1. Time from randomisation to spontaneous vaginal delivery [Within 1 week]

      Time measured from randomisation to the spontaneous vaginal delivery (delivery without the use of forceps, vacuum extraction, or a cesarean section)

    2. Time from PROM to delivery [Within 1 week]

      Time measured from prelabor rupture of membrane (leaking of amniotic fluid) until delivery

    3. Cesarean delivery rate [Within 1 week]

      Percentage of patients who deliver via cesarean section for whatever reason

    4. Instrumental delivery rate [Within 1 week]

      Percentage of patients who deliver via instrumental delivery (forceps, a vacuum device) for whatever reason

    5. Use of oxytocin [Within 1 week]

      Oxytocin used prior to the delivery of the baby. If oxytocin was used, we will measure how many international units (IU) of oxytocin were used from the beginning of labor to the delivery of the baby.

    6. Hyperstimulation with nonreassuring fetal heart rate tracing [Within 1 week]

      Percentage of uterine hyperstimulation- exaggerated uterine response consisting of uterine hypertonus, a single uterine contraction lasting two or more minutes or uterine tachysystole with a least 12 contractions in 20 minutes, with a simultaneous nonreassuring fetal heart rate tracing as defined by the 2015 FIGO (The international federation of gynaecology and obstetrics) classification of intrapartum cardiotocography.

    7. Rate of chorioamnionitis [Within 1 week]

      Clinical chorioamnionitis (a fever of 38.0°C or more plus one or more of the following: baseline fetal heart rate > 160 beats/minute for ≥ 10 minutes, maternal white cell count >15,000 cells/mm3 or purulent-appearing fluid coming from the cervical os visualized by speculum examination).

    8. Rate of endometritis [Within 3 weeks]

      Clinical endometritis (postpartum woman with at least two of the following signs or symptoms: fever ≥38.0°C, pain or tenderness (uterine or abdominal) with no other recognized cause or purulent drainage from the uterus.)

    9. Rate of postpartum maternal fever [Within 3 weeks]

      A fever of 38.0°C or more in the postpartum period.

    10. Use of antibiotics [Within 3 weeks]

      Possible use of antibiotics in the postpartum period.The decision of the need of antibiotics in the postpartum period is in the discretion of the physician.

    11. Lenght of antibiotic treatment [3 weeks]

      The decision of the need of antibiotics in the postpartum period is in the discretion of the physician. If antibiotics will be used, we will measure length of antibiotic treatment (in days).

    12. Number of neonates, admitted to intensive care unit [Within 3 weeks]

      Infants which will be admitted to the neonatal intensive unit for whatever reason.

    13. APGAR scores [Within 1 week]

      Infants with a 5-minute APGAR score of less than 7.The Apgar score is a number calculated by scoring the heart rate, respiratory effort, muscle tone, skin color, and reflex irritability of the infant, 5 min after birth. Each of these objective signs can receive 0, 1, or 2 points. The higher is the sum of the points, the better is the condition of the newborn.

    14. Maternal Length of Stay [Within 3 weeks]

      Total length of hospitalization of women in days.

    15. Rate of early neonatal sepsis [Within 3 weeks]

      Infants with early neonatal sepsis, a diagnosis based on a positive blood, cerebrospinal fluid, or urine microbiological culture in the first 72 hours after birth.

    16. Patients perception of labor (length, pain, overall satisfaction) [Within 3 weeks]

      Satisfaction and perceptions of woman giving birth with labour through a self-administered questionnaire that they will answer in the postpartum period (6 to 48 hours after labor). They will specify their level of agreement or disagreement on a symmetric 4-point agree-disagree scale (1- I strongly disagree, 2- I disagree, 3- I agree, 4- I strongly agree) for a series of statements regarding aspects of birth. With the beforementioned scale we will measure patients' perception of length of hospitalization before childbirth, perception of pain before admission to the labour room, pain associated with vaginal examinations and insertion of the vaginal insert and if they would choose the same method of managing birth in the next pregnancy.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 4 to12 hours after prelabour rupture of membranes

    • 18-50 years of age

    • Parity 0 to 2

    • Singleton pregnancy

    • Cephalic presentation

    • Term (37-41 6/7 weeks gestational age)

    • Bishop score ≤5

    • Reassuring fetal status

    Exclusion Criteria:
    • Uterine contractions

    • Signs of infection

    • Signs of non-reassuring fetal status

    • Meconium-stained amniotic fluid

    • Group B Streptococcus colonization

    • Fetal demise or major congenital anomaly

    • Intrauterine growth restriction (estimated fetal weight ≤ 3 percentile)

    • Contraindications for vaginal birth or use of prostaglandins for labor induction

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University Medical Centre Ljubljana

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Polona Peclin, Principal investigator, University Medical Centre Ljubljana
    ClinicalTrials.gov Identifier:
    NCT05430711
    Other Study ID Numbers:
    • 0120-115/2019/13
    First Posted:
    Jun 24, 2022
    Last Update Posted:
    Jun 24, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Polona Peclin, Principal investigator, University Medical Centre Ljubljana
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 24, 2022